{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:21:48Z","timestamp":1783167708515,"version":"3.54.6"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":148,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical and Health Technology Development Program in Shandong Province","award":["202301040579"],"award-info":[{"award-number":["202301040579"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Motivation<\/jats:title>\n                    <jats:p>Gene fusions resulting from genomic structural variation in somatic cells have been increasingly identified as central events driving oncogenesis. Ultra-deep targeted sequencing of driver fusions informs therapeutic selection in precision oncology. However, most structural variant (SV) callers were primarily architected for whole genome sequencing, failing to resolve the artifacts and alignment errors that drive false-positive calls in high-depth targeted data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here, we describe Fuscan, a robust DNA fusion caller specifically optimized for targeted sequencing data to identify oncogenic drivers. Fuscan improves sensitivity by focusing alignment on targeted driver sequences while simultaneously filtering homologous genomic regions to prevent false-positive partner-gene breakpoints. We performed targeted sequencing on 85 non-small cell lung cancer clinical specimens (comprising tissue and body fluids), four SV reference standards at 0.5% allele frequency, and 282 healthy-control leukocyte samples. We benchmarked Fuscan against established SV callers, achieving an area under the curve (AUC) of 0.992 and demonstrating its robustness in challenging clinical scenarios, including low-tumor-content tissues and liquid biopsies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Availability and implementation<\/jats:title>\n                    <jats:p>Fuscan is available on our GitHub repository: https:\/\/github.com\/YJmedLab\/Fuscan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bioadv\/vbag152","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:43:32Z","timestamp":1779968612000},"source":"Crossref","is-referenced-by-count":0,"title":["Fuscan: a robust DNA fusion caller for targeted sequencing data in cancer diagnostics"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9037-6602","authenticated-orcid":false,"given":"Zhaoying","family":"Liu","sequence":"first","affiliation":[{"name":"Shanghai Yijian Medical Laboratory Co., Ltd. , Shanghai, 201802,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Shanghai Yijian Medical Laboratory Co., Ltd. , Shanghai, 201802,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Chen","sequence":"additional","affiliation":[{"name":"Shanghai Yijian Medical Laboratory Co., Ltd. , Shanghai, 201802,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Feng","sequence":"additional","affiliation":[{"name":"The First Hospital of Zibo Department of Pathology, , Zibo, Shandong, 255200,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Hu","sequence":"additional","affiliation":[{"name":"The First Hospital of Zibo Department of Pathology, , Zibo, Shandong, 255200,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhou","sequence":"additional","affiliation":[{"name":"The First Hospital of Zibo Department of Pathology, , Zibo, Shandong, 255200,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6679-725X","authenticated-orcid":false,"given":"Dong","family":"Shi","sequence":"additional","affiliation":[{"name":"Shanghai Yijian Medical Laboratory Co., Ltd. , Shanghai, 201802,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"2026070408121586800_vbag152-B1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3390\/diagnostics10080521","article-title":"Next generation sequencing for gene fusion analysis in lung cancer: a literature review","volume":"10","author":"Bruno","year":"2020","journal-title":"Diagnostics"},{"key":"2026070408121586800_vbag152-B2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13059-021-02423-x","article-title":"GRIDSS2: comprehensive characterisation of somatic structural variation using single breakend variants and structural variant phasing","volume":"22","author":"Cameron","year":"2021","journal-title":"Genome Biol"},{"key":"2026070408121586800_vbag152-B3","doi-asserted-by":"crossref","first-page":"e0332407","DOI":"10.1371\/journal.pone.0332407","article-title":"Detection of leukemia gene fusions on DNA-level through targeted next-generation sequencing","volume":"20","author":"Chen","year":"2025","journal-title":"PLoS One"},{"key":"2026070408121586800_vbag152-B4","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/bioinformatics\/btv710","article-title":"Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications","volume":"32","author":"Chen","year":"2016","journal-title":"Bioinformatics"},{"key":"2026070408121586800_vbag152-B5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"key":"2026070408121586800_vbag152-B6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly (Austin)"},{"key":"2026070408121586800_vbag152-B7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jmoldx.2018.05.004","article-title":"Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA","volume":"20","author":"Clark","year":"2018","journal-title":"J Mol Diagn"},{"key":"2026070408121586800_vbag152-B8","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/1878-0261.12789","article-title":"Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing","volume":"14","author":"Cui","year":"2020","journal-title":"Mol Oncol"},{"key":"2026070408121586800_vbag152-B9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.lungcan.2017.10.011","article-title":"GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors","volume":"115","author":"Jiang","year":"2018","journal-title":"Lung Cancer"},{"key":"2026070408121586800_vbag152-B10","first-page":"656","article-title":"BLAT - The BLAST-like alignment tool","volume":"12","author":"Kent","year":"2002","journal-title":"Genome Res"},{"key":"2026070408121586800_vbag152-B11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nm.2644","article-title":"KIF5B-RET fusions in lung adenocarcinoma","volume":"18","author":"Kohno","year":"2012","journal-title":"Nat Med"},{"key":"2026070408121586800_vbag152-B12","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2026070408121586800_vbag152-B13","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtho.2020.10.156","article-title":"Potential unreliability of uncommon ALK, ROS1, and RET genomic breakpoints in predicting the efficacy of targeted therapy in NSCLC","volume":"16","author":"Li","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026070408121586800_vbag152-B14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","article-title":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"2026070408121586800_vbag152-B15","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.5858\/arpa.2018-0901-SA","article-title":"Circulating tumor DNA analysis in patients with cancer American Society of Clinical Oncology and College of American Pathologists Joint Review","volume":"142","author":"Merker","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"2026070408121586800_vbag152-B16","doi-asserted-by":"crossref","first-page":"e0264138","DOI":"10.1371\/journal.pone.0264138","article-title":"Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors","volume":"17","author":"Milbury","year":"2022","journal-title":"PLoS One"},{"key":"2026070408121586800_vbag152-B17","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1093\/bioinformatics\/btu549","article-title":"FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution","volume":"30","author":"Newman","year":"2014","journal-title":"Bioinformatics"},{"key":"2026070408121586800_vbag152-B18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jmoldx.2023.11.004","article-title":"An analytical pipeline with multiple software tools improves detection of cancer-associated gene fusions from genomic DNA","volume":"26","author":"Pan","year":"2024","journal-title":"J Mol Diagn"},{"key":"2026070408121586800_vbag152-B19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s11684-024-1118-y","article-title":"Non small cell lung cancer with SMARCA4 deficiency harboring rare EGFR mutations exhibited significant tumor response when treated with afatinib: a case report","volume":"19","author":"Qiu","year":"2025","journal-title":"Front Med"},{"key":"2026070408121586800_vbag152-B20","doi-asserted-by":"crossref","first-page":"I333","DOI":"10.1093\/bioinformatics\/bts378","article-title":"DELLY: structural variant discovery by integrated paired-end and split-read analysis","volume":"28","author":"Rausch","year":"2012","journal-title":"Bioinformatics"},{"key":"2026070408121586800_vbag152-B21","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.3390\/cancers13184705","article-title":"Current landscape of non-small cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy","volume":"13","author":"Rodak","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026070408121586800_vbag152-B22","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/modpathol.2017.181","article-title":"Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer","volume":"31","author":"Rosenbaum","year":"2018","journal-title":"Mod Pathol"},{"key":"2026070408121586800_vbag152-B23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"2026070408121586800_vbag152-B24","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-Line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"2026070408121586800_vbag152-B25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat Med"},{"key":"2026070408121586800_vbag152-B26","doi-asserted-by":"crossref","first-page":"102452","DOI":"10.1016\/j.xcrm.2025.102452","article-title":"A prognostic index integrating deep learning baseline PET\/CT biomarkers and multi-omics profiling in diffuse large B cell lymphoma","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep Med"},{"key":"2026070408121586800_vbag152-B27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1755-8794-7-23","article-title":"Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing","volume":"7","author":"Wong","year":"2014","journal-title":"BMC Med Genomics"},{"key":"2026070408121586800_vbag152-B28","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00432-022-03959-6","article-title":"The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients","volume":"149","author":"Wu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026070408121586800_vbag152-B29","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"}],"container-title":["Bioinformatics Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bioinformaticsadvances\/advance-article-pdf\/doi\/10.1093\/bioadv\/vbag152\/68431850\/vbag152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bioinformaticsadvances\/article-pdf\/6\/1\/vbag152\/68431850\/vbag152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bioinformaticsadvances\/article-pdf\/6\/1\/vbag152\/68431850\/vbag152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:12:25Z","timestamp":1783167145000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bioinformaticsadvances\/article\/doi\/10.1093\/bioadv\/vbag152\/8698026"}},"subtitle":[],"editor":[{"given":"Mikhail","family":"Dozmorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/bioadv\/vbag152","relation":{},"ISSN":["2635-0041"],"issn-type":[{"value":"2635-0041","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"vbag152"}}